Michael’s scientific training spans Chemistry and Biochemistry at the Max Planck Institute of Biochemistry and LMU Munich, with research experience across leading institutions including Harvard University, the German Center for Neurodegenerative Diseases, and the German Cancer Research Center. His doctoral work centered on developing molecular tools to investigate the biochemical principles of protein aggregation, with a focus on neurodegenerative disorders. At Scitaris, Michael combines his interdisciplinary research background with a sharp analytical mindset to support biotech and pharma clients in navigating strategic decisions across the drug development lifecycle.